Treatment outcomes and associated influencing factors among elderly patients with rifampicin-resistant tuberculosis: a multicenter, retrospective, cohort study in China | BMC Infectious Diseases

Written by

admin

in

  • World Health Organization. Global Tuberculosis Report 2024. 2024. https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2024

  • Bureau SS. Statistical bulletin of the National economic and social development of the people’s Republic of China in 2023. Chin Stat. 2024;03:4–21.

    Google Scholar 

  • Donald PR, Marais BJ, Barry CE. 3rd. Age and the epidemiology and pathogenesis of tuberculosis. Lancet (London England). 2010;375(9729):1852–4.

    PubMed 

    Google Scholar 

  • Pratt RH, Winston CA, Kammerer JS, Armstrong LR. Tuberculosis in older adults in the united states, 1993–2008. J Am Geriatr Soc. 2011;59(5):851–7.

    PubMed 

    Google Scholar 

  • Rajagopalan S. Tuberculosis in older adults. Clin Geriatr Med. 2016;32(3):479–91.

    PubMed 

    Google Scholar 

  • Wang L, Zhang H, Ruan Y, et al. Tuberculosis prevalence in china, 1990–2010; a longitudinal analysis of National survey data. Lancet (London England). 2014;383(9934):2057–64.

    PubMed 

    Google Scholar 

  • Mori T, Leung CC. Tuberculosis in the global aging population. Infect Dis Clin N Am. 2010;24(3):751–68.

    Google Scholar 

  • Negin J, Abimbola S, Marais BJ. Tuberculosis among older adults–time to take notice. Int J Infect Diseases: IJID : Official Publication Int Soc Infect Dis. 2015;32:135–7.

    Google Scholar 

  • Lv H, Zhang X, Zhang X, et al. Global prevalence and burden of multidrug-resistant tuberculosis from 1990 to 2019. BMC Infect Dis. 2024;24(1):243.

    PubMed 
    PubMed Central 

    Google Scholar 

  • Chaves-Torres NM, Fadul S, Patiño J, Netto E. Factors associated with unfavorable treatment outcomes in patients with rifampicin-resistant tuberculosis in Colombia 2013–2015: A retrospective cohort study. PLoS ONE. 2021;16(4):e0249565.

    PubMed 
    PubMed Central 

    Google Scholar 

  • Makhmudova M, Maxsumova Z, Rajabzoda A, Makhmadov A, van den Hof S, Mirtskhulava V. Risk factors for unfavourable treatment outcomes among rifampicin-resistant tuberculosis patients in Tajikistan. Int J Tuberculosis Lung Disease: Official J Int Union against Tuberculosis Lung Disease. 2019;23(3):331–6.

    Google Scholar 

  • Alemu A, Bitew ZW, Worku T. Poor treatment outcome and its predictors among drug-resistant tuberculosis patients in ethiopia: A systematic review and meta-analysis. Int J Infect Diseases: IJID : Official Publication Int Soc Infect Dis. 2020;98:420–39.

    Google Scholar 

  • Li H, Mei J, Su W. Analysis of the treatment outcomes and influencing factors of rifampicin-resistant pulmonary tuberculosis patients aged 65 and above in China from 2015 to 2021. Chin J Tuberculosis. 2025;47(04):408–15.

    Google Scholar 

  • Ye Z, Ren F, Wang H. Treatment outcomes and influencing factors in elderly patients with multidrug/rifampicin-resistant pulmonary tuberculosis: a National multicenter, retrospective cohort study. Chin J Tuberculosis. 2024;46(09):1023–9.

    Google Scholar 

  • Cantalice Filho JP, Bóia MN, Sant Anna CC. [Analysis of the treatment of pulmonary tuberculosis in elderly patients at a university hospital in Rio de janeiro, brazil]. Jornal Brasileiro De Pneumologia: Publicacao Oficial Da Sociedade Brasileira De Pneumologia E Tisilogia. 2007;33(6):691–8.

    PubMed 

    Google Scholar 

  • Bele S, Jiang W, Lu H, et al. Population aging and migrant workers: bottlenecks in tuberculosis control in rural China. PLoS ONE. 2014;9(2):e88290.

    PubMed 
    PubMed Central 

    Google Scholar 

  • Organization WH. World Health Organization. Global Tuberculosis Report. 2018. https://www.who.int/publications/i/item/9789241565646

  • Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443–54.

    PubMed 
    PubMed Central 

    Google Scholar 

  • Workneh MH, Bjune GA, Yimer SA. Prevalence and associated factors of tuberculosis and diabetes mellitus comorbidity: A systematic review. PLoS ONE. 2017;12(4):e0175925.

    PubMed 
    PubMed Central 

    Google Scholar 

  • Liu Q, Li W, Xue M, et al. Diabetes mellitus and the risk of multidrug resistant tuberculosis: a meta-analysis. Sci Rep. 2017;7(1):1090.

    PubMed 
    PubMed Central 

    Google Scholar 

  • Zou L, Kang W, Guo C, et al. Treatment outcomes and associated influencing factors among patients with Rifampicin-Resistant tuberculosis: A multicenter, retrospective, cohort study in China. Infect Drug Resist. 2024;17:3737–49.

    PubMed 
    PubMed Central 

    Google Scholar 

  • Lecai J, Mijiti P, Chuangyue H, Qian G, Weiguo T, Jihong C. Treatment outcomes of multidrug-resistant tuberculosis patients receiving ambulatory treatment in shenzhen, china: a retrospective cohort study. Front Public Health. 2023;11:1134938.

    PubMed 
    PubMed Central 

    Google Scholar 

  • Ma JB, Zeng LC, Ren F, et al. Treatment outcomes and risk factors of Multidrug-Resistant tuberculosis patients in xi’an china, a retrospective cohort study. Infect Drug Resist. 2022;15:4947–57.

    PubMed 
    PubMed Central 

    Google Scholar 

  • Conradie F, Diacon AH, Ngubane N, et al. Treatment of highly Drug-Resistant pulmonary tuberculosis. N Engl J Med. 2020;382(10):893–902.

    PubMed 
    PubMed Central 

    Google Scholar 

  • Guglielmetti L, Khan U, Velásquez GE, et al. Oral regimens for Rifampin-Resistant, Fluoroquinolone-Susceptible tuberculosis. N Engl J Med. 2025;392(5):468–82.

    PubMed 
    PubMed Central 

    Google Scholar 

  • Tola H, Holakouie-Naieni K, Mansournia MA, et al. National treatment outcome and predictors of death and treatment failure in multidrug-resistant tuberculosis in ethiopia: a 10-year retrospective cohort study. BMJ Open. 2021;11(8):e040862.

    PubMed 
    PubMed Central 

    Google Scholar 

  • Kuaban A, Balkissou AD, Ekongolo MCE, Nsounfon AW, Pefura-Yone EW, Kuaban C. Incidence and factors associated with unfavourable treatment outcome among patients with rifampicin-resistant pulmonary tuberculosis in yaoundé, Cameroon. Pan Afr Med J. 2021;38:229.

    PubMed 
    PubMed Central 

    Google Scholar 

  • Caraux-Paz P, Diamantis S, de Wazières B, Gallien S. Tuberculosis in the elderly. J Clin Med. 2021;10(24). https://doi.org/10.3390/jcm10245888

  • Udwadia Z, Vendoti D. Totally drug-resistant tuberculosis (TDR-TB) in india: every dark cloud has a silver lining. J Epidemiol Commun Health. 2013;67(6):471–2.

    Google Scholar 

  • Yin J, Wang X, Zhou L, Wei X. The relationship between social support, treatment interruption and treatment outcome in patients with multidrug-resistant tuberculosis in china: a mixed-methods study. Trop Med Int Health: TM IH. 2018;23(6):668–77.

    PubMed 

    Google Scholar 

  • Wagnew F, Alene KA, Kelly M, Gray D. The effect of undernutrition on sputum culture conversion and treatment outcomes among people with multidrug-resistant tuberculosis: a systematic review and meta-analysis. Int J Infect Diseases: IJID : Official Publication Int Soc Infect Dis. 2023;127:93–105.

    Google Scholar 

  • Chakhaia T, Blumberg HM, Kempker RR et al. Lack of weight gain and increased mortality during and after treatment among adults with drug-resistant tuberculosis in Georgia, 2009–2020. medRxiv: the preprint server for health sciences. 2024.

  • Badawi A, Gregg B, Vasileva D. Systematic analysis for the relationship between obesity and tuberculosis. Public Health. 2020;186:246–56.

    PubMed 

    Google Scholar 

  • Hu S, Guo J, Chen Z, Gong F, Yu Q. Nutritional indices predict all cause mortality in patients with Multi-/Rifampicin-Drug resistant tuberculosis. Infect Drug Resist. 2024;17:3253–63.

    PubMed 
    PubMed Central 

    Google Scholar 

  • Johnston JC, Shahidi NC, Sadatsafavi M, Fitzgerald JM. Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis. PLoS ONE. 2009;4(9):e6914.

    PubMed 
    PubMed Central 

    Google Scholar 

  • Chiang CY, Enarson DA, Yu MC, et al. Outcome of pulmonary multidrug-resistant tuberculosis: a 6-yr follow-up study. Eur Respir J. 2006;28(5):980–5.

    PubMed 

    Google Scholar 

  • Keshavjee S, Gelmanova IY, Farmer PE, et al. Treatment of extensively drug-resistant tuberculosis in tomsk, russia: a retrospective cohort study. Lancet (London England). 2008;372(9647):1403–9.

    PubMed 

    Google Scholar 

  • Chan ED, Strand MJ, Iseman MD. Treatment outcomes in extensively resistant tuberculosis. N Engl J Med. 2008;359(6):657–9.

    PubMed 

    Google Scholar 

  • Stephanie F, Saragih M, Tambunan USF. Recent progress and challenges for Drug-Resistant tuberculosis treatment. Pharmaceutics. 2021;13(5).

  • Wallis RS, O’Garra A, Sher A, Wack A. Host-directed immunotherapy of viral and bacterial infections: past, present and future. Nat Rev Immunol. 2023;23(2):121–33.

    PubMed 

    Google Scholar 

  • Mi J, Liang Y, Liang J, et al. The research progress in immunotherapy of tuberculosis. Front Cell Infect Microbiol. 2021;11:763591.

    PubMed 
    PubMed Central 

    Google Scholar 

  • Barzegari S, Afshari M, Movahednia M, Moosazadeh M. Prevalence of anemia among patients with tuberculosis: A systematic review and meta-analysis. Indian J Tuberc. 2019;66(2):299–307.

    PubMed 

    Google Scholar 

  • Singla R, Raghu B, Gupta A, et al. Risk factors for early mortality in patients with pulmonary tuberculosis admitted to the emergency room. Pulmonology. 2021;27(1):35–42.

    PubMed 

    Google Scholar 

  • Ashenafi S, Bekele A, Aseffa G, et al. Anemia is a strong predictor of wasting, disease severity, and progression, in clinical tuberculosis (TB). Nutrients. 2022;14:16.

    Google Scholar 

  • de Mendonça EB, Schmaltz CA, Sant’Anna FM, et al. Anemia in tuberculosis cases: A biomarker of severity? PLoS ONE. 2021;16(2):e0245458.

    PubMed 
    PubMed Central 

    Google Scholar 

  • Nagu TJ, Spiegelman D, Hertzmark E, et al. Anemia at the initiation of tuberculosis therapy is associated with delayed sputum conversion among pulmonary tuberculosis patients in Dar-es-Salaam, Tanzania. PLoS ONE. 2014;9(3):e91229.

    PubMed 
    PubMed Central 

    Google Scholar 

  • Isanaka S, Mugusi F, Urassa W, et al. Iron deficiency and anemia predict mortality in patients with tuberculosis. J Nutr. 2012;142(2):350–7.

    PubMed 

    Google Scholar 

  • Morris CD, Bird AR, Nell H. The haematological and biochemical changes in severe pulmonary tuberculosis. Q J Med. 1989;73(272):1151–9.

    PubMed 

    Google Scholar 

  • Shin DM, Jo EK. Antimicrobial peptides in innate immunity against mycobacteria. Immune Netw. 2011;11(5):245–52.

    PubMed 
    PubMed Central 

    Google Scholar 

  • Hella J, Cercamondi CI, Mhimbira F, et al. Anemia in tuberculosis cases and household controls from tanzania: contribution of disease, coinfections, and the role of Hepcidin. PLoS ONE. 2018;13(4):e0195985.

    PubMed 
    PubMed Central 

    Google Scholar 

  • Kerkhoff AD, Meintjes G, Burton R, Vogt M, Wood R, Lawn SD. Relationship between blood concentrations of Hepcidin and anemia severity, mycobacterial burden, and mortality among patients with HIV-Associated tuberculosis. J Infect Dis. 2016;213(1):61–70.

    PubMed 

    Google Scholar 

  • Gil-Santana L, Cruz LAB, Arriaga MB, et al. Tuberculosis-associated anemia is linked to a distinct inflammatory profile that persists after initiation of antitubercular therapy. Sci Rep. 2019;9(1):1381.

    PubMed 
    PubMed Central 

    Google Scholar 

  • Gu P, Lu P, Ding H, et al. Effectiveness, cost, and safety of four regimens recommended by WHO for RR/MDR-TB treatment: a cohort study in Eastern China. Ann Med. 2024;56(1):2344821.

    PubMed 
    PubMed Central 

    Google Scholar 

  • Lan Z, Ahmad N, Baghaei P, et al. Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet Respiratory Med. 2020;8(4):383–94.

    Google Scholar 

  • Zou F, Cui Z, Lou S, et al. Adverse drug events associated with linezolid administration: a real-world pharmacovigilance study from 2004 to 2023 using the FAERS database. Front Pharmacol. 2024;15:1338902.

    PubMed 
    PubMed Central 

    Google Scholar 

  • Guglielmetti L, Jaspard M, Le Dû D et al. Long-term outcome and safety of prolonged bedaquiline treatment for multidrug-resistant tuberculosis. Eur Respir J. 2017;49(3).

  • Brust JCM, Gandhi NR, Wasserman S, et al. Effectiveness and cardiac safety of Bedaquiline-Based therapy for Drug-Resistant tuberculosis: A prospective cohort study. Clin Infect Diseases: Official Publication Infect Dis Soc Am. 2021;73(11):2083–92.

    Google Scholar 

  • Jin Y, Benkeser D, Kipiani M, et al. The effect of anti-tuberculosis drug pharmacokinetics on QTc prolongation. Int J Antimicrob Agents. 2023;62(4):106939.

    PubMed 
    PubMed Central 

    Google Scholar 

  • Kuhlin J, Davies Forsman L, Osman A, et al. Increased risk of adverse drug reactions by higher linezolid dose per weight in multidrug-resistant tuberculosis. Int J Antimicrob Agents. 2024;64(4):107302.

    PubMed 

    Google Scholar 

  • Frippiat F, Bergiers C, Michel C, Dujardin JP, Derue G. Severe bilateral optic neuritis associated with prolonged linezolid therapy. J Antimicrob Chemother. 2004;53(6):1114–5.

    PubMed 

    Google Scholar 

  • Korotych O, Achar J, Gurbanova E, et al. Effectiveness and safety of modified fully oral 9-month treatment regimens for rifampicin-resistant tuberculosis: a prospective cohort study. Lancet Infect Dis. 2024;24(10):1151–61.

    PubMed 
    PubMed Central 

    Google Scholar 

  • Sotgiu G, Centis R, D’Ambrosio L, et al. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. Eur Respir J. 2012;40(6):1430–42.

    PubMed 

    Google Scholar 

    • Continue Reading

    More posts